A Study to Compare and Evaluate Intrahepatic cccDNA Reduction After Administrating Clevudine or Entecavir in the Chronic HBV Patients.

Trial Profile

A Study to Compare and Evaluate Intrahepatic cccDNA Reduction After Administrating Clevudine or Entecavir in the Chronic HBV Patients.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 22 Dec 2014

At a glance

  • Drugs Clevudine (Primary) ; Entecavir
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Bukwang Pharmaceutical
  • Most Recent Events

    • 17 Dec 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 25 Jul 2012 Planned end date changed from 1 Aug 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
    • 31 Dec 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top